| Previous close | 445.86 |
| Open | 444.85 |
| Bid | 426.01 x 1400 |
| Ask | 439.82 x 1100 |
| Day's range | 432.17 - 445.85 |
| 52-week range | 196.78 - 555.77 |
| Volume | 1,367,542 |
| Avg. volume | 1,158,132 |
| Market cap | 64.11B |
| Beta (5Y monthly) | 1.02 |
| PE ratio (TTM) | 98.74 |
| EPS (TTM) | 4.45 |
| Earnings date | 28 Apr 2021 - 03 May 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 413.67 |
- Financial Times
Genomic sequencing head calls for ‘Bio Force’ to detect virus threats
The chief executive of the world's largest genomic sequencing technology company has called for global co-operation to track new virus variants, arguing it is essential to ensure that Covid-19 vaccines, drugs, and diagnostics do not fail in the face of new strains. Francis De Souza, who leads the Californian company Illumina, said governments and companies should create a “global surveillance network” to monitor and share information on the virus, just as many have tried to do with threats from computer viruses. Illumina, whose shares have soared 60 per cent in the past year, has been expanding its capacity to build the sequencers and deliver the materials they need to run.
- Business Wire
Illumina and the University Hospital of Tübingen Evaluate Potential of Whole Genome Sequencing to Improve Diagnosis of Full Range of Genetic Diseases
Illumina partners with the University of Tubingen to study the value of whole-genome sequencing as a diagnostic for patients with genetic diseases
- FX Empire
Illumina Rockets After Topping Q4 Earnings
Illumina shares jumped 11.87% Friday after the genomic sequence company delivered impressive quarterly results.
